Forced expression of the cell cycle inhibitor p57Kip2 in cardiomyocytes attenuates ischemia-reperfusion injury in the mouse heart

Table 2 Description of experimental animals and cardiac functional parameters

	Control	*R26loxp-TAp57* ^k/+ *; Mlc2v-cre* ^k/+
	n = 6	n = 4
Age (days old)	136 ± 22	133 ± 23
Body Weight (grams)	32 ± 1	34.2 ± 1
Heart Weight (mg)	162 ± 2	214 ± 2
Heart/Body Weight Ratio (mg/g)	5.03 ± 0.45	6.19 ± 0.75
Baseline functional parameters
LVSP (mmHg)	97 ± 9	107 ± 3
LVEDP (mmHg)	3.4 ± 1.4	2 ± 1
LVDP (mmHg)	94 ± 10	105 ± 3
HR (bpm)	418 ± 22	387 ± 24
RPP (bpm × mmHg)	37,920 ± 3,064	41,218 ± 2,794
dP/dt max (mmHg/sec)	2,461 ± 262	2,764 ± 180
CF (ml/min)	4.53 ± 0.24	4.58 ± 0.26
Functional Parameters post I/R
LVSP (mmHg)	75 ± 3.5	87 ± 11
LVEDP (mmHg)	39 ± 4.3	23 ± 8
LVDP (mmHg)	30 ± 6*	63 ± 15*
HR (bpm)	362 ± 37	368 ± 17
RPP (bpm × mmHg)	10,361 ± 2,077**	22,787 ± 4,858**
dP/dt max (mmHg/sec)	944 ± 193	1,513 ± 332
CF (ml/min)	2.38 ± 0.24**	3.5 ± 0.5**

Values are means ± SE. The two asterisks (**) indicate statistical significance with a probability of p < 0.05 (unpaired t-test), while the one asterisk indicates a probability of p = 0.05. One-way ANOVA followed by Fisher post hoc test also indicated significant difference among these groups. There was also a strong trend for lower LVEDP in the transgenic hearts; however with the small number of tested animals this did not reach statistical significance. LVSP, left ventricular systolic pressure; LVEDP, left ventricular end diastolic pressure; LVDP, left ventricular developed pressure, HR, heart rate; RPP, rate pressure product; CF, coronary flow.

ISSN: 1472-6793